로딩 중…
지수 로딩 중…
JW PHARMACEUTICAL
001060· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩26,700-2.02%
2026-06-19
Price Chart
JW PHARMACEUTICAL+17.88%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 621.73B KRW |
| Revenue | 789.95B KRW |
| Net Income | 71.52B KRW |
| Total Assets | 621.61B KRW |
| Net Assets | 381.78B KRW |
| Employees | 1,107 |
| Value | |
| P/E | 8.69x |
| P/B | 1.63x |
| PEG | 0.15x |
| P/S | 0.79x |
| EV/EBITDA | 23.43x |
| FCF Yield | 13.61% |
| Profitability | |
| ROE | 18.73% |
| ROA | 11.51% |
| Op. Margin | 13.42% |
| Revenue Growth | 7.91% |
| Earnings Growth | 57.31% |
| Financial Health | |
| Debt Ratio | 162.82% |
| Total Debt | 32.10B KRW |
| FCF | 84.62B KRW |
| Cash | 20.55B KRW |
| Current Ratio | 1.46x |
| Net Debt/EBITDA | 0.43x |
| Dividend | |
| Div. Yield | 2.39% |
| Div. Growth | 44.44% |
| Performance | |
| 1Y Return | 17.88% |
| 1M Return | -5.82% |
| From 52W High | -31.97% |
| 1Y MDD | -37.39% |
| Trading | |
| Volume | 75,767 shares |
| Foreign Own. | 8.27% |
| Per Share | |
| EPS | 2,872 KRW |
| BPS | 15,804 KRW |
Company Info
The company began as Joseon Choongwae Pharmaceutical Laboratory in 1945, incorporated in 1953, and expanded its business in 2019 by acquiring Vietnamese Euvipharm after listing in 1976. It holds products such as Livalo, Hemlibra, Trupass, Actemra, and the 3rd-generation 3-chamber nutritional infusion Winuf. The company leads the market with its combined novel drug of pitavastatin and ezetimibe. Utilizing the JWAVE platform, it applies AI models across the entire new drug development cycle to reduce time and cost. JW Pharmaceutical is headquartered in Gwacheon, Gyeonggi-do.